- Home>
- Specialties>
- Oncology and Hematology>
- Carcinoma
Search for Carcinoma in Oncology and Hematology
Physician-authored summaries on the latest research on carcinoma, editorials on carcinoma, and perspectives on carcinoma - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 296 results - Relevance
- Date
You searched for: carcinoma in Oncology and Hematology
-
Tamoxifen Effective for Ductal Carcinoma in Situ
- March 27, 2012
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
In women with estrogen receptor–positive disease, adjuvant tamoxifen reduced risk for subsequent breast cancer.- Reviewing:
- Allred DC et al., J Clin Oncol 2012 Mar 5;:
-
Radiotherapy and Tamoxifen for Ductal Carcinoma in Situ
- January 18, 2011
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Following local excision, radiotherapy had long-lasting benefits and tamoxifen had small absolute benefits for breast cancer outcomes.- Reviewing:
- Cuzick J et al., Lancet Oncol 2011 Jan; 12:21. Silverstein MJ and Lagios MD., J Natl Cancer Inst Monogr 2010; 2010:193. Pinder SE et al., Br J Cancer 2010 Jun 29; 103:94. Eng-Wong J et al., J Natl Cancer Inst Monogr 2010; 2010:200.
-
For Managing Ductal Carcinoma in Situ, How Important Is Choice of Surgeon?
- January 18, 2011
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Type of treatment and presence of positive margins varied substantially among breast surgeons.- Reviewing:
- Dick AW et al., J Natl Cancer Inst 2011 Jan 19; 103:92.
-
Adjuvant Chemotherapy for Bladder Cancer
- September 21, 2010
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Highest-risk patients received a survival benefit.- Reviewing:
- Svatek RS et al., Clin Cancer Res 2010 Sep 1; 16:4461.
-
Combination Targeted Therapy for Patients with Advanced Renal Cancer
Bevacizumab plus everolimus was tolerated by most patients, but this combination might not be more effective than single-agent targeted therapy.- Reviewing:
- Hainsworth JD et al., J Clin Oncol 2010 May 1; 28:2131.
-
Pazopanib: A New Tool for Advanced Renal Cancer
- April 6, 2010
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Compared with placebo, this angiogenesis inhibitor was associated with better responses and prolonged progression-free survival.- Reviewing:
- Sternberg CN et al., J Clin Oncol 2010 Feb 20; 28:1061.
-
Omitting Radiation for Patients with DCIS
- November 3, 2009
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Local tumor excision alone yielded acceptably low rates of local recurrence in patients with low- and intermediate-grade DCIS.- Reviewing:
- Hughes LL et al., J Clin Oncol 2009 Oct 13;:
-
Sunitinib for “Real World” Renal Cancer Patients
- September 1, 2009
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
In an expanded-access study, sunitinib demonstrated efficacy in high-risk populations.- Reviewing:
- Gore ME et al., Lancet Oncol 2009 Aug; 10:757. Choueiri TK and Bellmunt J., Lancet Oncol 2009 Aug; 10:740.
-
Survival After Resection of Hepatocellular Carcinoma
Tumor size >2 cm, tumor multifocality, and microvascular invasion predicted poor prognoses among patients with early disease.- Reviewing:
- Nathan H et al., Ann Surg 2009 May; 249:799.
-
Adjuvant Vaccine Therapy for Advanced Renal Cell Carcinoma
- August 5, 2008
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Postnephrectomy patients who received vitespen had similar recurrence-free survival compared with those who were merely observed.- Reviewing:
- Wood C et al., Lancet 2008 Jul 12; 372:145. Yang JC., Lancet 2008 Jul 12; 372:92.
-
Everolimus for Advanced Renal Cell Carcinoma
- July 29, 2008
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Progression-free survival was longer for patients who received everolimus than for those who received placebo.- Reviewing:
- Motzer RJ et al., Lancet 2008 Jul 22;:
-
Bevacizumab plus Interferon for Advanced Renal Cancer
- January 8, 2008
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Bevacizumab plus interferon was effective in patients with untreated metastatic clear-cell renal cancer.- Reviewing:
- Escudier B et al., Lancet 2007 Dec 22/29; 370:2103.
-
MRI to Diagnose Pure DCIS?
- October 2, 2007
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
About half of biopsy-proven high-grade DCIS that was visualized with MRI was mammographically occult.- Reviewing:
- Kuhl CK et al., Lancet 2007 Aug 11; 370:485.
-
Clinical Outcomes in Patients with Residual DCIS After Neoadjuvant Chemotherapy
- July 16, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Breast cancer patients with residual noninvasive cancer did as well as those with no residual cancer.- Reviewing:
- Mazouni C et al., J Clin Oncol 2007 Jul 1; 25:2650-5.
-
Preoperative Therapy in Patients with Esophageal Cancer Free
- July 9, 2007
- David H. Ilson, MD, PhD
- Oncology and Hematology
Preoperative chemotherapy plus radiotherapy improves survival.- Reviewing:
- Gebski V et al., Lancet Oncol 2007 Mar; 8:226-34.
-
Adjuvant Therapy for Adrenal Cancer Free
Mitotane prolonged recurrence-free survival following radical resection.- Reviewing:
- Terzolo M et al., N Engl J Med 2007 Jun 7; 356:2372-80. Schteingart DE., N Engl J Med 2007 Jun 7; 356:2415-8.
-
Survival Benefit from mTOR Inhibition in Advanced Kidney Cancer Free
Compared with interferon, temsirolimus improved overall survival in patients with metastatic renal-cell carcinoma.- Reviewing:
- Hudes G et al., N Engl J Med 2007 May 31; 356:2271-81.
-
Selecting Appropriate Patients with Hepatocellular Carcinoma for Liver Transplantation Free
- April 23, 2007
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Tumor size and number of lesions should remain the major determinants of eligibility.- Reviewing:
- Pawlik TM et al., Ann Surg 2007 Mar; 245:435-42.
-
Sorafenib for Patients with Advanced Kidney Cancer Free
- January 10, 2007
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Development of sorafenib, sunitinib, bevacizumab, and temsirolimus has been predicated on pioneering work in molecular genetics and tumor biology of renal-cell cancer.- Reviewing:
- Escudier B et al., N Engl J Med 2007 Jan 11; 356:125-34.
-
Sunitinib vs. Interferon-α in Patients with Metastatic Renal Carcinoma
- January 10, 2007
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Patients treated with sunitinib had a median progression-free survival that was significantly longer than that of patients who received interferon.- Reviewing:
- Motzer RJ et al., N Engl J Med 2007 Jan 11; 356:115-24. Brugarolas J., N Engl J Med 2007 Jan 11; 356:185-7.
Sort by:
Items 1 to 20 of 296 results - Relevance
- Date
